How Estonians are empowered with their health data.
View as Webpage
Leverage data for better healthcare outcomes. Learn from national leaders in the field. >>
 
 
 
Subscribe
 
 
 
February 11, 2020
 
apple watch
 
 

The accuracy of wearables employing photoplethysmography (PPG)-based heart rate sensors may vary significantly between specific devices and activity types, but these sensors’ performances do not appear to be significantly affected by the skin tone of the wearer, according to a new study published in NPJ Digital Medicine.

The investigation, conducted by Duke University researchers among 53 individuals, highlighted consistent over-reporting of heart rate during low-intensity activity, accuracy and output differences between consumer- and research-grade devices, and other concerns that are “especially important for researchers and clinicians to be aware of when choosing devices for clinical research and clinical decision support,” the researchers wrote in the study.

“We started this study because we were seeing some evidence, both in research and anecdotally, that indicated that wearable devices weren’t working as well for people with darker skin tones,” Jessilyn Dunn, an assistant professor of biomedical engineering at Duke and an author on the paper, said in a statement from the university. “People would compare a reading on a chest strap to their smart watch and get different heart rate values. The companies that manufacture these devices don’t put out any metrics about how well they work across skin tones, so we wanted to collect evidence about how well they work and identify potential circumstances where they may not work well.”

In particular, it also explored whether these types of devices and sensors could inadvertently be playing a role in healthcare innovation inequality.

“To date, no studies have systematically validated wearables under various movement conditions across the complete range of skin tones, and particularly on skin tones at the darkest end of the spectrum,” the researchers wrote. “To our knowledge, this is the first reported characterization of wearable sensors across the complete range of skin tones. Validation of wearable devices during activity and across all skin tones is critical to enabling their equitable use in clinical and research applications.”

TOPLINE DATA

Skin tone was not found to be a statistically significant driver of either mean directional error or mean absolute error across the collective devices. Here, while at-rest participants with the second-darkest skin tone logged the greatest mean directional error and and the lightest had the lowest, at-rest absolute error was greatest among the darkest skin tone and lowest among those with the second darkest skin tone. There were also no difference in heart rate variability between skin tones.

The researchers did identify significant differences when measuring skin tone accuracy differences across specific devices; however, this effect was based on the performance of the Biovotion wearable which showed lower resting heart rates and higher active heart rates.

In contrast to skin tones, the researchers did see major accuracy errors during physical activity, and when comparing the readings of specific devices.

At rest, the Xiaomi Miband 3 recorded the highest mean absolute error (10.2 bpm) while the Apple Watch 4 recorded the lowest (4.4 bpm). For research wearables, the Biovotion Everion was highest (16.5 bpm) while the Empatica E4 was lowest (11.3 bpm). For standard deviation of the mean absolute average, included to measure accuracy consistency, the Fibit Charge 2 (7.3) and Apple Watch 4 (2.7) represented the full range across consumer devices while the Empatica E4 (8.0) and the Biovotion Everion (6.4) did so for research devices.

During physical activity, mean absolute error among consumer devices was greatest in the Xiaomi Miband 3 (13.8 bpm) and lowest in the Apple Watch 4 (4.6 bpm), while for research devices the Biovotion (19.8) and Empatica E4 (12.8) punctuated the readings. Standard deviations for these categories ranged between the Garm Vivosmart 3 (9.2) and the Apple Watch 4 (3.0), and the Empatica E4 (8.5) and Biovotion Everion (5.3).

The specific types of activities also drove some differences in sensor accuracy.

“We found that there was a bigger drop in accuracy during activities that involved wrist motion that could introduce motion artifacts, like typing, and we saw a drop in accuracy during deep breathing, which could indicate the devices locking onto cyclic behavior, like breathing, rather than heart rate,” Dunn said.

Across all these measurements, the Apple Watch 4 was the top performer, followed by the Garmin Vivosmart 3.

“We were initially surprised that the commercial devices were more accurate, but they also have huge user bases, so they’re able to use lots of data to clean up their signals and improve their algorithms,” she said. “The research wearables are just using raw data, which is important for researchers and clinicians to be aware of.”

HOW IT WAS DONE

Researchers enrolled participants across a range of skin tones who did not have skin conditions or sensitivities, and were not currently taking medications or substances that could affect heart rate.

These participants wore commercial (Apple Watch 4, Fitbit Charge 2, Garmin Vivosmart 3 and Xiaomi Miband 3) and research wearables (Empatica E4, Biovotion Everion) on each wrist, as well as an ECG patch that was used as the baseline for heart rate measurements. Each was asked to perform tasks that ranged from timed walks, a typing task and sitting at rest.

THE LARGER TREND

The devices being measured by the Duke researchers are increasingly finding themselves at the heart of healthcare research. Following the large-scale Apple Heart Study conducted by Stanford Medicine researchers, Apple has gone on to announce open participation in a handful of new health trials run in partnership with major universities and health groups. Fitbit, meanwhile, has long seen its activity trackers employed by trials looking for inexpensive, user friendly sensors.

Researchers have previously questioned whether the activity trackers in wearables and other smart devices are reliable enough for clinical use. Somewhat recently, that conversation has turned toward whether light-based sensors, computer vision and machine learning could be introducing unintended biases to digital health efforts.

IN CONCLUSION

“While the research-grade wearables are the only wearables that provide users with raw data that can be used to visualize PPG waveforms and calculate [heart rate variability] the [heart rate] measurements tended to be less accurate than consumer-grade wearables. This is especially important for researchers and clinicians to be aware of when choosing devices for clinical research and clinical decision support. It is our hope that this analysis framework can act as a guide for researchers, clinicians and health consumers to evaluate such tradeoffs when exploring potential wearable devices for use in a clinical study, digital biomarker development, clinical practice, or in personal health monitoring,” the researchers wrote.

 
Woman using smartphone
 
 

As cases of the COVID-19 (the novel coronavirus) continue to spread across China and beyond, the Chinese government has released a new app intended to help citizens check whether they came into contact with the virus. 

App users are asked to register a phone number, name and ID number in or to see if they were in contact with someone infected, according to Chinese state media outlet Xinhua, which first reported the story. 

Users are able to get the app by scanning a QR code through platforms like WeChat, Alipay and QQ. The app will then give them information on whether they came into “close contact” with the disease, which the government defines as being in a close distance to someone with no protection who has a confirmed case or a suspected case. 

The tool will act as a way of collecting data as well as to educate citizens on what to do if they have been in close contact with the virus — which is to stay at home and get advice from health authorities. 

The latest tool, which was released on Saturday, was developed by the General Office of State Council, the National Health Commission and China Electronics Technology Group Corporation (CETC), according to Xinhua. 

WHY IT MATTERS 

Since COVID-19 was first identified in Wuhan China in late December, the number of cases has been on the rise. As of yesterday the World Health Organization has reported 40,554 cases of the virus. Of those reported cases, 40,325 are in China. The death toll is also rising with over 900 people in China having died from the disease. 

China’s government has kicked into action. Its efforts include building two new hospitals in Wuhan to handle the crisis and the mass spraying of disinfectant on city streets in attempts to prevent the spread. 

It has also made regional health leadership changes recently. Chinese state media reported that Zhang Jin, party secretary of the Health Commission of Hubei Province, where the novel coronavirus was first identified, and Liu Yingzi, director of the Hubei Provincial Health Commission, have been fired.

The release of the new app stands alongside these efforts and, ideally, could bring timely exposure information to a greater number of those at risk of infection.

THE LARGER TREND 

As the COVID-19 continues to spread innovators are looking to use tech to help track and elevate the problem. 

For example, HealthMap, a digital epidemiology tool developed by a team at Boston Children’s Hospital, has been actively tracking the disease spread through social media networks, chatrooms and other online crowdsourcing efforts. 

It has recently joined forces with chatbot Buoy Health on a new tool that lets patients check their symptoms at home. HealthMap gives Buoy data about what is happening the region, and Buoy can provide HealthMap info on trends happening in the patient’s home.  

In January VivaLNK, a Santa Clara, California-based connected health startup, announced that Shanghai Public Health Clinical Center (SPHCC) is using the startup’s continuous temperature sensor to curb the spread of coronavirus in China. Instead of physically checking the patient temperature every few hours with a mercury thermometer, temperatures can be monitored remotely and automatically, thereby limiting patient-to-caregiver contact.

Also in late January Singapore-based Veredus Laboratories, maker of tech-enabled molecular diagnostic solutions, announced the development of VereCoV detection kit, a portable Lab-on-Chip application capable of detecting the COVID-19, as well as other influenzas. 

 
 
ADVERTISEMENT
The College of St. Scholastica
 
 
 
The funds will help the mental health startup expand its global footprint.

Keep Reading >>
 
 
 
The microgravity research will take place in a miniature laboratory onboard a nanosatellite. 

Keep Reading >>
 
 
Call for Proposals
 
This is a peer-to-peer event and we are particularly interested in how hospitals and health systems have implemented machine learning and AI to improve care, control costs, and drive operational efficiencies – in short, to provide better, more patient-centric care, achieve strategic goals, and create a more sustainable organization.
 
 
 
Palisades Growth Capital led the round, which brings the startup's total raise to over $7 million.

Keep Reading >>
 
 
 
Interest rates remain at historic lows and purchase price multipliers will likely be attractive to purchasers.

Keep Reading >>
 
 
 
Reducing the rate of healthcare-associated infections and securing patient information are key when aiming to achieve high quality patient care, says Benjamin Philippe, EMEA Healthcare Sales and Business Development Lead at HP Inc.

Watch Now >>
 
 
 
Estonia's citizens have full access to how their data is used in managing their healthcare, which helps ensure trust remains high between the appropriate stakeholders, says Kalle Killar, deputy secretary general at the country's Ministry of Social Affairs

Watch Now >>
 
 
By HIMSS Insights
 
Connected Care is about patients moving smoothly from their home through the continuum of care and back, depending on their medical needs and facilitated by data that is immediately available wherever it's needed. Making data available is about interoperability, but in a broad sense. IT tools have to be able to communicate, and so do the people involved. Healthcare made some progress recently with technical standards, but are we improving human-to-human interoperability too?

Download the ebook now >>
 
 
ADVERTISEMENT
HIMSS20
 
ASSESSING EMERGING TECHNOLOGIES
 
What you need to know
 
Today, industry players are zeroing in on the best ways to assess these new technologies coming into the market. But each stakeholder has a different priority — which means a different way of evaluating these tools. This month MobiHealthNews will be taking a closer look at how digital tools are validated and assessed by health systems, payers and investors.
 
 
 
 
 
2 Monument Sq., Ste 400 Portland, ME 04101
 
 
.